Fidelity Investments’s Gain Therapeutics GANX Stock Holding History

Fidelity Investments’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-80	Closed	-$154	–	5390
2025 Q1	$154	Buy	+80	New	+$177	﹤0.01%	5094

Other funds holding GANX

GAM

Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

DCM

DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Fidelity Investments's GANX Position: Q2 2025 in Review

Fidelity Investments sold out of Gain Therapeutics (GANX) in Q2 2025, closing a stake of 80 shares — an estimated $154 sold.

Fidelity Investments first reported a position in GANX in Q1 2025 and held it in 1 quarter. The position peaked at $154 in Q1 2025. 35 funds tracked by Wall St. Rank hold GANX as of Q2 2025.

Fidelity Investments reported no remaining Gain Therapeutics position as of Q2 2025 after selling out during the quarter.
Fidelity Investments sold 80 Gain Therapeutics shares in Q2 2025, an estimated $154.
Fidelity Investments first reported a position in Gain Therapeutics in Q1 2025 and held it in 1 quarter.
Fidelity Investments's Gain Therapeutics position peaked at $154 in Q1 2025.
35 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2025.

Based on Fidelity Investments's 13F filing for Q2 2025, filed 14 Aug 2025.